期刊文献+

血清CA125检测对卵巢上皮性癌预后的价值 被引量:6

The prognostic value of the serum CA125 detection in patients with epithelial ovarian carcinoma
下载PDF
导出
摘要 目的:探讨血清CA125在卵巢上皮性癌中的预后价值。方法:采用回顾性分析方法,对2000年1月~2003年5月中国医科大学附属第一医院妇科收治的60例上皮性卵巢癌患者手术前后血清CA125水平,及其结合病理、分期及预后等临床资料进行分析。结果:术前血清CA125水平与组织类型和临床分期相关(P<0.05),术后CA125半衰期>20d者,复发率高于≤20d者,而复发的中位时间短于≤20d者(P<0.05)。多因素分析表明:临床分期和CA125半衰期对预后有影响。术后CA125水平的升高可预测复发。结论:上皮性卵巢癌患者术前测定血清CA125水平可初步判断组织类型及临床分期,术后监测血清CA125水平可及时发现复发,并可判断预后。 Objective: To discuss the prognostic value of the serum CA125 in patients with epithelial ovarian carcinoma.Methods:60 patients with epithelial ovarian carcinoma underwent operation in this Hospital between January 2000 and May 2003.Correlation analysis among the serum CA125 level and histological type, FIGO stage were carried out retrospectively.Results:The serum CA125 level before operation was related to histological type and FIGO staging(P<0.05). The recurrent rate in patients with half-life >20 days was higher than those ≤20 days.In contrast, the recurrent mean time was shorter than those ≤20 days (P<0.05). Analysis of prognostic multi-factors showed: FIGO stage and estimate the half-life of CA125 were prognostic factors. The increase of the serum CA125 level after operation usually indicated recurrence.Conclusion:The serum CA125 level before operation of epithelial ovarian cancer can help know the histological type and FIGO stage. This marker is useful in the early detection of recurrence and interpretable prognosis.
作者 黄立 姚嘉斐
出处 《中国妇幼保健》 CAS 北大核心 2005年第13期1566-1568,共3页 Maternal and Child Health Care of China
关键词 CA125 半衰期 卵巢上皮癌 预后 CA125 Half-life Epithelial ovarian carcinoma Prognosis
  • 相关文献

参考文献8

  • 1Van der Burgh MEL, Lammes FB, van Putten WLJ et al. The prognostic value of the serum half- time of CA125 during the induction of chemotherapy. Gynecol Oncol, 2003, 30 (6): 307.
  • 2Markowska J, Wilkoszarska J, Emerich J et al. Factors influencing period of time between negative second - look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland. Eur J Gynaecol Oncol,2004, 21: 164 ~ 167.
  • 3Geiser JP, Miller GA, Lee TH et al. Relationship of preoperative serum CA125 to survival in epithelial ovarian carcinoma. J Reprod Med,2002, 41: 140 ~ 142.
  • 4马水清,沈铿,郎景和.恶性肿瘤风险指数在卵巢恶性肿瘤术前诊断中的作用[J].中华妇产科杂志,2001,36(3):162-164. 被引量:33
  • 5Hogdall CK, Hording U, Norgaard - Pedersen B et al. Serum tetranectin and CA125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol, 2003, 57: 175 ~ 178.
  • 6Low RN, Saleh F, Song S et al. Treated ovarian cancer: comparison of MR imaging with serum CA125 level and physical examination - a longitudinal study. Radiology, 2001,211: 519 ~528.
  • 7Kurokawa T, Yoshida Y, Kawahara K. Whole - body PET with FDG is useful for following up an ovarian cancer patient with only rising CA125levels within the normal range. Ann Nucl Med, 2002, 16 (7): 491 ~493.
  • 8Wilder JL, PavlikE , Straughan JI et al. Clinical implications of a rising serum CA125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol, 2003, 89 (2):233 ~ 235.

二级参考文献3

  • 1Giuseppe M,Br J Obstet Gynaecol,1999年,106卷,524页
  • 2Tingulstad S,Br J Obstet Gynaecol,1996年,103卷,826页
  • 3Gillis C R,Lancet,1991年,337卷,611页

共引文献32

同被引文献27

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部